Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Japanese Subjects With Advanced Solid Tumors

NCT05685472 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05685472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05685472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Japanese Subjects With Advanced Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
December 8, 2022
Completion date
July 29, 2025
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors